GET DAILY SIGNALSBrightSpring Health Services (BTSG) Reports +26.4% Revenue Growth in Q3 2026
Key Takeaways
- Net revenue rose 26.4% year over year to $4.21 billion, ahead of the roughly $3.87 billion consensus estimate.
- Adjusted EPS (earnings per share) of $0.54 topped the $0.47 analyst consensus by about 14.7%.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $228 million grew 42% year over year and beat expectations.
- Management raised full-year 2026 revenue and Adjusted EBITDA guidance across both business segments.
- Pharmacy Solutions revenue grew 26% and Provider Services revenue grew 31% year over year.
- Leverage declined to 1.79x, reflecting stronger cash generation and balance-sheet flexibility.
- For more on BTSG's Major News, Today's Price Move, Price Targets, and Forecasts, explore the dedicated pages.
- Explore Trending AI Robots to see AI-driven trading strategies in action.
Earnings Context and Why It Matters
BrightSpring Health Services is a leading provider of home- and community-based health services for complex, medically vulnerable populations, serving roughly 500,000 patients daily across all 50 states. The company's two operating segments — Pharmacy Solutions and Provider Services — sit at the center of healthcare's shift toward lower-cost, patient-preferred care settings. This quarterly earnings report matters because it tests whether BTSG can sustain the double-digit growth it has delivered since its 2024 initial public offering while absorbing a major strategic change: the March 2026 divestiture of its Community Living business. Investors also watch closely for evidence that specialty and infusion pharmacy momentum, driven by limited distribution drug launches, can offset reimbursement pressures elsewhere in the business. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
BrightSpring reported third quarter 2026 net revenue of $4.21 billion, up 26.4% from $3.33 billion in the prior-year period and above the analyst consensus estimate of roughly $3.87 billion. Gross profit increased 32.3% to $519 million, while net income from continuing operations reached $101 million, compared with $38 million a year earlier.
Adjusted EBITDA climbed 42.0% to $228 million, exceeding the approximately $214.8 million consensus. Adjusted EPS came in at $0.54, comfortably ahead of the $0.47 estimate. By segment, Pharmacy Solutions revenue rose 26% to $3.73 billion, and Provider Services revenue rose 31% to $481 million. The company also reduced its leverage ratio to 1.79x as of September 30, 2026, from 2.15x at the end of the prior quarter.
Management raised full-year 2026 guidance, now projecting revenue of $15.9 billion to $16.125 billion and Adjusted EBITDA of $850 million to $860 million. From what I see, the broad-based improvement across segments points to solid operational execution.
Market Reaction and Investor Sentiment
Shares of BTSG rose sharply in the wake of the report, with the stock surging roughly 7.1% to about $64.50, according to market data compiled after the announcement. The positive reaction reflected a clean beat across the board — revenue, Adjusted EPS, and Adjusted EBITDA all landed above consensus — combined with a guidance increase that suggests momentum is extending into the fourth quarter and beyond.
Investor sentiment was further supported by broad-based segment strength. Pharmacy Solutions benefited from specialty and infusion script growth and a growing portfolio of limited distribution drug (LDD) launches, while Provider Services gained from strong home health census and the contribution of recently acquired Amedisys and LHC branches. The combination of top-line growth and margin improvement reinforced confidence in the company's execution.
Forward Outlook and Key Factors to Monitor
Following this quarter's results, investors will focus on whether BTSG can sustain its growth trajectory into 2027. Management reiterated its expectation for at least 15% to 20% organic Adjusted EBITDA growth next year, though now off a larger 2026 base. Sustaining that pace will depend on continued specialty and infusion expansion, an active pipeline of new limited distribution drug launches, and successful integration of acquired branches.
Several factors warrant close attention. In Pharmacy Solutions, the Home and Community Pharmacy business is absorbing an estimated $200 million full-year revenue impact from the Inflation Reduction Act (IRA), a federal law affecting drug pricing, along with the company's exit from uneconomic customers. Underlying growth in that line has nevertheless improved through the year, and management expects continued progress.
On the Provider Services side, home health census growth, de novo expansion, and value-based care programs — including a new LEAD ACO (Accountable Care Organization) Medicare program starting in January — represent key catalysts. Margin trends, clinician retention, and the pace of cash-flow conversion will also remain central to the investment thesis as the company balances growth with disciplined capital deployment. I'm watching this closely as the company moves into the new year.
Using Tickeron’s AI Tools in Practice
In my own research process, I often turn to Tickeron’s AI Screener to quickly filter healthcare names and compare fundamentals like revenue growth and EBITDA margins against peers. It helps surface comparable opportunities without spending hours on manual screens, which is especially useful when tracking names like BTSG that operate in evolving sectors. This kind of tool complements traditional analysis by highlighting technical patterns and AI-driven signals that might otherwise go unnoticed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BTSG in -2.91% downward trend, falling for three consecutive days on October 27, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BTSG declined for three days, in 87 of 121 cases, the price declined further within the following month. The odds of a continued downward trend are 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
BTSG broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BTSG entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 21 of 23 cases where BTSG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on BTSG as a result. In 40 of 46 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for BTSG just turned positive on October 30, 2026. Looking at past instances where BTSG's MACD turned positive, the stock continued to rise in 20 of 23 cases over the following month. The odds of a continued upward trend are 87%.
BTSG moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BTSG crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +12.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where BTSG advanced for three days, in 168 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. BTSG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.460) is normal, around the industry mean (4.728). P/E Ratio (37.579) is within average values for comparable stocks, (13.238). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.915) is also within normal values, averaging (6.065).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BTSG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement